European Journal of Epidemiology

, Volume 18, Issue 11, pp 1079–1083 | Cite as

Immunity to measles in the Croatian population

  • Berislav Borčić
  • Renata Mažuran
  • Bernard Kaić


In the frame of measles elimination activities, sera from 1205 Croatian citizens from all parts of the country and of all ages were tested, using Gull Laboratories ELISA, for measles IgG. Equivocal results were found in 50 subjects. Of the remaining 1155 participants, 118 or 10.2% were negative and 1037 or 89.8% positive. The proportion of seronegatives ranged from zero (age groups 41–50, 51 and more) up to 21.4% (1 year of age). As for their distribution into age groups suggested by the European Regional Office of WHO, there were 12.7, 8.9, 9.5 and 8.8% negatives in age groups 1–4, 5–9, 10–14 and 15+ years, respectively. According to these results, only the first two age groups meet WHO criteria, indicating that vaccination coverage higher than the reported 90–94% should be attained if one is to expect measles elimination.

Croatia Herd immunity Measles 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organization. Measles elimination. URL: Scholar
  2. 2.
    Compulsory Immunization Coverage in Croatia. Croatian Health Service Yearbook. Croatian National Institute of Public Health. Zagreb 1990-2001.Google Scholar
  3. 3.
    Borčić B, Ljubičić M, Gjenero-Margan I, et al. Trends in EPI target diseases in Croatia. Third world congress on vaccines and immunisation. Abstracts. Opatija 2002; 78.Google Scholar
  4. 4.
    EPI Information System. Global Summary, September 1998. World Health Organization document WHO/ EPI/GEN/98.10.Google Scholar
  5. 5.
    de Melker H, et al. The seroepidemiology of measles in Western Europe. Epidemiol and Infect 2001; 126(2): 249–259.Google Scholar
  6. 6.
    European Advisory Group on the Expanded Programme on Immunization. World Health Organization document EUR/ICP/CMDS 01 01 11(A).Google Scholar
  7. 7.
    Measles Eradication: Recommendation from a Meeting Cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. Morb Mortal Wkly Rep 1997; 46(RR-11): 1–20.Google Scholar
  8. 8.
    European Advisory Group on the Expanded Programme on Immunization. World Health Organization document EUR/ICP/CMDS 01 01 06.Google Scholar
  9. 9.
    Ramsey A. A strategic framework for the elimination of measles in the European Region. World Health Organization document EUR/ICP/CMDS 01 01 05.Google Scholar
  10. 10.
    World Health organization. Expanded Programme on Immunization. Epidemiological situation of vaccine-preventable diseases. Croatia. Wkly Epidemiol Rec 1994; 42(Suppl. 1): 1–3.Google Scholar
  11. 11.
    Dilraj A, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: A randomized trial. Lancet 2000; 355: 798–803.PubMedGoogle Scholar
  12. 12.
    Osborne K, et al. Ten years of serological surveillance in England and Wales: Methods, results, implications and action. Int J Epidemiol 2000; 29: 362–368.PubMedGoogle Scholar
  13. 13.
    Hesketh L, et al. An evaluation of nine commercial EIA kits for the detection of specific IgG. J Virol Meth 1997; 66: 51–59.Google Scholar
  14. 14.
    Gay NJ, et al. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun Dis Rep Rev 1997; 7: R17–R21.Google Scholar
  15. 15.
    Paunio M, Hedman K, Davidkin I, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: High occurrence among teenagers vaccinated at a young age. Epidemiol Infect 2000; 124(2): 263–271.PubMedGoogle Scholar
  16. 16.
    Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: A 12-year follow-up in two cohorts. Vaccine 1998; 16(20): 2052–2057.PubMedGoogle Scholar
  17. 17.
    Markowitz LE, Albrecht P, Orenstein WA, Lett SM, Pugliese TJ, Farrell D. Persistence of measles antibody after revaccination. J Infect Dis 1992; 166(1): 205–208.PubMedGoogle Scholar
  18. 18.
    Borcic B, Smerdel S, Abu Eldan J, et al. The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine. Lijec Vjesn 1989; 111(4-5): 131–134.PubMedGoogle Scholar
  19. 19.
    Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine. J Epidemiol Community Health 1999; 53(3): 173–178.PubMedGoogle Scholar
  20. 20.
    Weibel RE, Buynak EB, McLean AA, Hilleman MR. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. Pediatrics 1978; 61(1): 5–11.PubMedGoogle Scholar
  21. 21.
    Ikić D, Smerdel S, Weisz-Malačk R, et al. Field trial with combined and simultaneously applied viral and bacterial vaccines. JAZU. Zagreb 1972; 121–131.Google Scholar
  22. 22.
    The Immunological basis for Immunization Series. Module 7: Measles. World Health Organization document WHO/EPI/GEN/93. 17.Google Scholar
  23. 23.
    Abu Eldan J, BorčIć B, Smerdel S. Persistence of immunity against measles in persons immunized with the Edmonston-Zagreb vaccine. Acta med Croatica 1991; 45: 297–304.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Berislav Borčić
    • 1
  • Renata Mažuran
    • 2
  • Bernard Kaić
    • 1
  1. 1.Croatian National Institute of Public HealthZagrebCroatia
  2. 2.Institute of Immunology Inc.ZagrebCroatia

Personalised recommendations